FDA Drug Safety Reform Must Come From Outside Agency – Sen. Grassley
This article was originally published in The Pink Sheet Daily
Executive Summary
Oversight of the agency's drug safety functions is "going to have to be outside the FDA," Senate Finance Committee Chairman Grassley tells HHS Secretary Leavitt. Grassley still wants drug safety reviewers to have guaranteed independence from the Office of New Drugs, despite plans for a new Drug Safety Oversight Board.